Online inquiry

IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ844MR)

This product GTTS-WQ844MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ844MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10450MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ4987MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ15812MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ10376MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ13085MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ13738MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ12468MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ9882MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA KB001-A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW